Eczema cream safety during pregnancy under scrutiny: new study compares ruxolitinib to steroids

NCT ID NCT06627335

Recruiting now Knowledge-focused Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will analyze health records of over 5,600 pregnant women with atopic dermatitis (eczema) to compare infant outcomes between those who used ruxolitinib cream (Opzelura) and those who used topical corticosteroid creams. Researchers will look at rates of major birth defects, small-for-gestational-age births, and other pregnancy outcomes. The goal is to better understand the safety of these treatments during pregnancy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ruxolitinib cream (Opzelura) and topical corticosteroids
What this could lead to: If successful, this study could provide important safety information about using ruxolitinib cream during pregnancy for women with atopic dermatitis.
What could go wrong: This is an observational study using existing claims data, not a controlled trial. It can show associations but not prove cause and effect. Results may be limited by data accuracy and unmeasured factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema pregnancy disorder Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS PREGNANCY RELATED

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Syneos Health (remote site)
RECRUITING

Morrisville, North Carolina, 27560, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.